Morningstar Sees Value in LPL, Fiserv and Nu After a Weak Year

Financial stocks lagged the broader market as higher rates and AI concerns changed investor expectations. Morningstar favors LPL Financial, Fiserv and Nu, but each thesis depends on a different operational proof point.
Financial services entered the final quarter of 2026 far behind the broader market. The Financial Select Sector SPDR Fund had gained about 0.8% for the year when the source was published, compared with nearly 14% for the SPDR S&P 500 ETF Trust.
Morningstar argues that investors have overreacted in three cases: LPL Financial, Fiserv and Nu Holdings. The common theme is valuation, but the operating questions are different.
LPL must defend cash economics
LPL has been recovering toward mid- to high-single-digit organic net new asset growth. Morningstar's long-term case rests on adviser recruitment, high asset retention and scale in independent wealth management.
The risk is client sweep cash, which the analyst says contributes about 30% to 35% of gross profit. AI-enabled cash tools or changes in customer behavior could reduce that profit pool. LPL needs either a credible alternative way to monetize cash or evidence that the feared disruption is limited. Morningstar's $543 fair-value estimate implied roughly 68% upside from the price cited in the source.
Fiserv needs stabilization
Morningstar calls 2026 a reset year for Fiserv. It still sees advantages from scale in merchant acquiring and issuer processing, along with high switching costs in bank technology. Clover gives the company a path to sell more services to small businesses.
The thesis requires mid-single-digit revenue growth and stable margins. A double-digit free-cash-flow yield can signal undervaluation, but it can also reflect concern that earnings will deteriorate. Morningstar's $106 estimate implied about 130% upside, making stabilization the central proof point.
Nu must manage credit while expanding
Nu became a leading digital bank in Brazil through low costs and strong profitability. It is expanding elsewhere in Latin America and considering the United States. Morningstar believes investors placed too much weight on Brazilian unemployment, inflation and credit-quality concerns.
Its $16.60 fair-value estimate implied about 11% upside, much less than the estimates for LPL and Fiserv. That smaller gap suggests the market already recognizes more of Nu's growth.
These are not one trade. LPL depends on cash monetization, Fiserv on operational repair and Nu on credit performance. The useful way to follow the picks is to test those company-specific milestones rather than assume a financial-sector rebound will lift all three.
Continue your LPLA research
Related News
NYSE Extends Options Trading, but Early Volume Shows the Limits
NYSE added premarket and post-close options sessions for 29 heavily traded stocks and funds. The launch answers demand for longer trading access, but thin initial volume highlights liquidity and execution risks.
Bank OZK's Rising Dividend Is Well Covered, but Credit Still Sets the Limit
Bank OZK raised its quarterly dividend for a 65th straight quarter. A payout near one-third of earnings provides room, while construction-loan credit remains the main constraint.
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Parabilis Heads Into ESMO With Strong Early Data and a High Bar
Parabilis will present updated zolucatetide data in desmoid tumors on Oct. 24. Early responses were strong, but investors still need durability, safety and a credible Phase 3 dose.
Pfizer's 5.8% Yield Depends on Cash Flow Catching Up
Pfizer's dividend remains covered by adjusted earnings, but 2025 free cash flow fell short of distributions. Debt and patent expirations leave management less room to restore dividend growth.















Latest comments